Page 206 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 7
References
1. Silvestris N, Maiello E, De Vita F, et al. Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treat Rev. 2010;36 Suppl 3:S46-55.
2. Venturini M. Rational development of capecitabine. Eur J Cancer. 2002;38 Suppl 2:3-9.
3. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23-44.
4. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA.
1990;264(11):1444-1450.
5. Bosset JF, Pavy JJ, Hamers HP, et al. Determination of the optimal dose of 5-fluorouracil when
combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three
consecutive phase II studies. EORTC Radiotherapy Group. Eur J Cancer. 1993;29a(10):1406-1410.
6. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles.
Nat Clin Pract Oncol. 2007;4(2):86-100.
7. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate
with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J
Clin Oncol. 2000;18(6):1337-1345.
8. Dunst J, Reese T, Sutter T, et al. Phase I trial evaluating the concurrent combination of radiotherapy
and capecitabine in rectal cancer. J Clin Oncol. 2002;20(19):3983-3991.
9. Ngan SY, Michael M, Mackay J, et al. A phase I trial of preoperative radiotherapy and capecitabine
for locally advanced, potentially resectable rectal cancer. Br J Cancer. 2004;91(6):1019-1024.
10. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of
a randomized phase III study. J Clin Oncol. 2001;19(8):2282-2292.
11. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous
fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase
III study. J Clin Oncol. 2001;19(21):4097-4106.
12. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon
cancer. N Engl J Med. 2005;352(26):2696-2704.
13. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine (Xeloda) and concomitant
boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys.
2006;66(3):762-771.
14. Dunst J, Debus J, Rudat V, et al. Neoadjuvant capecitabine combined with standard radiotherapy
in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther
Onkol. 2008;184(9):450-456.
15. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of
5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47(8):2203-2206.
16. KNMP. Royal Dutch Society for the Advancement of Pharmacy. Fluorouracil/Capecitabine DPD gene activity score and guidelines. [Website]. 2015; https://kennisbank.knmp.nl/article/
farmacogenetica/2552-4893-4894.html. Accessed 05 May 2017.
17. Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing:
2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216.
18. Henricks LM, Lunenburg CATC, Meulendijks D, et al. Translating DPYD genotype into DPD
phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015.
204